Bhubaneswar: The World Health Organization (WHO) has recommended two new drugs – Eli Lilly & Co.’s rheumatoid arthritis drug and GlaxoSmithKline Plc’s monoclonal antibody – for treating patients with COVID-19.
According to the WHO Guideline Development Group, Lilly’s Baricitinib drug is “strongly recommended” for patients with severe or critical disease in combination with corticosteroids. It is a Janus kinase (JAK) inhibitor- a class of drugs used to treat autoimmune conditions, blood and bone marrow cancers, and rheumatoid arthritis.
The recommendation is based on “moderate certainty evidence” that it improves survival and reduces the need for ventilation.
The experts have advised against the use of two other JAK inhibitors (ruxolitinib and tofacitinib) in such cases.
The WHO has recommended the use of a monoclonal antibody, known as Sotrovimab, in non-severe cases. The drug should only be administered to patients at the highest risk of hospitalisation, such as the elderly, people with immunodeficiencies or chronic diseases such as diabetes.
Last year, the WHO had approved Regeneron Pharmaceuticals Inc’s monoclonal antibody to treat COVID patients.
Baripada: A newborn girl was found lying near a bush at Bhanra village under Karanjia…
Mumbai: Salman Khan and Shah Rukh Khan, the leading superstars of Bollywood, came from different…
Mumbai: Actor-filmmaker Dhanush took to his X handle on Friday to announce the release date…
Chennai: Odisha all but booked a berth in the knockout stage of the 14th Hockey…
Cuttack: Several traffic restrictions have been imposed to ensure smooth movement of devotees to Dhabaleswar…
Mumbai: Sidhu Moose Wala's parents Balkaur Singh and Charan Kaur shared a picture of their…
New York: A group of American women has launched an unprecedented protest against men who…
Bhubaneswar: Four more handicrafts were granted approval by the Odisha government, taking the total number…